New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:09 EDTAGENAgenus announces 'promising' Prophage G-200 Phase 2 results
Agenus announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as "exciting" and a "very promising therapy" in an editorial published in Neuro-Oncology. The results of Agenus’ Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months. The results of the Phase 2 trial have garnered the support of the National Cancer Institute. The study is actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria.
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:08 EDTAGENAgenus reports Q4 EPS (41c), consensus (16c)
Reports Q4 revenue $1.62M, consensus $620K. Target Milestones for 2015 include: Publication of the Phase 2 data for Prophage in newly diagnosed GBM in a peer reviewed journal. Explore options for the advancement of Prophage for newly diagnosed GBM to a Phase 3 trial. Full Phase 3 data for partner GlaxoSmithKline’s HZ/su shingles vaccine are expected to be presented at a scientific conference and submitted for publication in a peer-reviewed journal. The vaccine contains Agenus’ proprietary QS-21 Stimulon adjuvant. EMA regulatory decision on GlaxoSmithKline’s malaria vaccine candidate RTS,S, which contains Agenus’s QS-21 Stimulon adjuvant. File Investigational New Drug applications for two checkpoint modulator antibody programs as part of our global oncology alliance with Incyte.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use